Albert Bourla, Pfizer CEO (AP Photo/Markus Schreiber)

Up­dat­ed: Pfiz­er sticks to 2025 pro­jec­tions as Covid sales sta­bi­lize, R&D re­vamp con­tin­ues

Pfiz­er’s high-pro­file, high-volatil­i­ty Covid-19 fran­chise sta­bi­lized at the end of 2024, as the New York drug­mak­er pur­sues a re­vamp of its R&D op­er­a­tions and con­tin­ues …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland